Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4530207 | 0.85 | DHODH (0.57) | KDM4EDHODHALDH1A1GAARAB9A | |
| SCHEMBL30536524 | 0.85 | DHODH (0.57) | KDM4EDHODHALDH1A1GAARAB9A | |
| SCHEMBL4584445 | 0.84 | MAPT (0.55) | KDM4EALDH1A1SYKAURKARPS6KB1 | |
| Hydrochloric Acid SCHEMBL22609596 | 0.83 | MAPT (0.54) | KDM4EALDH1A1SYKAURKARPS6KB1 | |
| SCHEMBL16007613 | 0.82 | SIGMAR1 (0.56) | KDM4EGAAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8691797 | 0.81 | DHODH (0.52) | HCRTR1HCRTR2KDM4EDHODHALDH1A1 | |
| SCHEMBL17941266 | 0.81 | ALDH1A1 (0.60) | HCRTR1HCRTR2KDM4EALDH1A1RAB9A | |
| SCHEMBL15689013 | 0.79 | ALDH1A1 (0.56) | KDM4EDHODHALDH1A1GAARAB9A | |
| SCHEMBL28282980 | 0.79 | MAPK8 (0.52) | KDM4EALDH1A1SYKAURKARPS6KB1 | |
| SCHEMBL3718998 | 0.78 | MAPT (0.52) | KDM4EALDH1A1SYKGAAAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4209388-B2 | — | — | 2009-01-14 | — | — | JP | claimed |
| EP-1519936-B1 | METHOD OF MAKING NEVIRAPINE | BOEHRINGER INGELHEIM CHEMICALS (US) | 2008-01-02 | — | — | EP | claimed |
| CN-1280293-C | Improved process for the preparation of nevirapine | BOEHRINGER INGELHEIM CHEMICALS (US) | 2006-10-18 | — | — | CN | claimed |
| JP-2005533083-A | — | — | 2005-11-04 | — | — | JP | claimed |
| EP-1519936-A1 | IMPROVED METHOD OF MAKING NEVIRAPINE | Boehringer Ingelheim Chemicals, Inc. (US) | 2005-04-06 | — | — | EP | claimed |
| US-6680383-B1 | REACTING 2-HALO-3-PYRIDINECARBONITRILE WITH CYCLOPROPYLAMINE, THEN HYDROLYZING TO FORM 2-HALONICOTINIC ACID, AMIDATING AND CYCLIZING TO FORM DRUGS USED AS POLYMERASE INHIBITORS; VIRAL DISEASES | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2004-01-20 | — | — | US | claimed |
| WO-2004002988-A1 | IMPROVED METHOD OF MAKING NEVIRAPINE | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2004-01-08 | — | — | WO | claimed |
| US-20040002603-A1 | Method for making nevirapine | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2004-01-01 | — | — | US | claimed |
| CN-110218211-B | Simple preparation method of nevirapine | 新发药业有限公司 | 2020-06-23 | — | — | CN | disclosed |
| CN-110218211-A | A kind of simple and convenient process for preparing of nevirapine | 新发药业有限公司 | 2019-09-10 | — | — | CN | disclosed |
| WO-2016118586-A1 | LOWCOST, HIGH YIELD SYNTHESIS OF NEVIRAPINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20090123516-A1 | DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS-THERAPEUTIC SAMS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-05-14 | — | — | US | disclosed |
| EP-1519936-B1 | METHOD OF MAKING NEVIRAPINE | BOEHRINGER INGELHEIM CHEMICALS (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1519936-B1 | METHOD OF MAKING NEVIRAPINE | BOEHRINGER INGELHEIM CHEMICALS (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6680383-B1 | REACTING 2-HALO-3-PYRIDINECARBONITRILE WITH CYCLOPROPYLAMINE, THEN HYDROLYZING TO FORM 2-HALONICOTINIC ACID, AMIDATING AND CYCLIZING TO FORM DRUGS USED AS POLYMERASE INHIBITORS; VIRAL DISEASES | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6680383-B1 | REACTING 2-HALO-3-PYRIDINECARBONITRILE WITH CYCLOPROPYLAMINE, THEN HYDROLYZING TO FORM 2-HALONICOTINIC ACID, AMIDATING AND CYCLIZING TO FORM DRUGS USED AS POLYMERASE INHIBITORS; VIRAL DISEASES | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| WO-2004002988-A1 | IMPROVED METHOD OF MAKING NEVIRAPINE | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002988-A1 | IMPROVED METHOD OF MAKING NEVIRAPINE | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20040002603-A1 | Method for making nevirapine | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20040002603-A1 | Method for making nevirapine | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002603-A1 | Method for making nevirapine | IDH1, IDH3B, CBR3 | HCRTR1 908/4885HCRTR2 1507/4885KDM4E 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.